- Home
- Oncology latest news
Oncology latest news
Below you’ll find the most recent oncology news across Johnson & Johnson.
Janssen Seeks Approval of a New Indication for IMBRUVICA® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
Application based on Phase 3 SHINE study results, which investigated the safety and efficacy of all-oral ibrutinib in combination with bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma[1]
Janssen Presents New Data Demonstrating the Combination of Niraparib and Abiraterone Acetate Plus Prednisone Significantly Improved Radiographic Progression-Free Survival as a First-Line Therapy in Patients with HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Initial results from Phase 3 MAGNITUDE study, to be featured in a late-breaking oral presentation at ASCO GU, highlight subset of patients with mCRPC most likely to benefit from treatment
New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Real-world evidence study demonstrates majority of patients with mCSPC achieved over 90 percent decline in PSA by six months after initiation of ERLEADA® Rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer as shown by separate post-hoc analysis of patient-reported outcomes from Phase 3 SPARTAN and TITAN studies
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Initial results from Phase 3 MAGNITUDE study of niraparib in combination with abiraterone acetate plus prednisone as a first-line therapy in patients with metastatic castration-resistant prostate cancer featured as an oral presentation New data for ERLEADA® (apalutamide) build on more than a decade of experience in prostate cancer; updated clinical trial information for novel drug delivery system TAR-200 plus cetrelimab in early-stage bladder cancer to be presented
News Archive
Looking for more news? Visit the archive to see a full list of oncology updates from the past several years.
More from Johnson & Johnson
Caring & giving around the globe: 43 Johnson & Johnson programs that are transforming lives—and the future of healthcare
Check out this fun interactive map for a glimpse at how the company is helping people on nearly every continent live healthier lives.
Doing good day and night: 6 Johnson & Johnson employees who are making the world a better place
Who says you can’t take your work home with you? For these men and women, their day jobs are just one facet of living a purpose-driven life to help others in truly impactful ways.
How Johnson & Johnson is pioneering in the fight against the world’s #1 cancer killer
The doctor overseeing the company’s new Lung Cancer Initiative reveals why it’s uniquely qualified to work on thwarting the disease—and why he’s uniquely qualified to oversee its efforts.